Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3281507 | 0.84 | HDAC6 (0.69) | MYCHPGDLMNAMEN1KMT2A | |
| SCHEMBL3282222 | 0.83 | MGAM (0.54) | MYCHPGDLMNAMEN1KMT2A | |
| SCHEMBL3286990 | 0.82 | NPC1 (0.52) | MYCHPGDTSHRRAB9AMEN1 | |
| SCHEMBL3281222 | 0.81 | MYC (0.53) | MYCHPGDLMNAKMT2AALDH1A1 | |
| SCHEMBL3281301 | 0.81 | ALDH1A1 (0.58) | MYCHPGDLMNARAB9AMEN1 | |
| SCHEMBL3281265 | 0.81 | MYC (0.54) | MYCHPGDALDH1A1KDM4E | |
| SCHEMBL4511791 | 0.79 | HSP90AA1 (0.60) | HPGDTSHRLMNAHSP90AA1HSP90AB1 | |
| SCHEMBL28052395 | 0.79 | MYC (0.56) | MYCHPGDLMNAMEN1KMT2A | |
| SCHEMBL3095946 | 0.79 | HPGD (0.71) | MYCHPGDLMNARAB9AKMT2A | |
| SCHEMBL3281249 | 0.79 | MYC (0.55) | MYCHPGDLMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705017-B2 | Compounds for treatment of neurodegenerative diseases | EN VIVO PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | ENVIVO PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004041-A1 | Compounds for treatment of neurodegenerative diseases | HDAC5, HDAC6, HDAC3 | MYC 4493/4885HPGD 489/4885TSHR 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.